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Arrhythmias and sudden death
AbstrAct
Aims Obesity is an increasing health problem and is 
an important risk factor for the development of atrial 
fibrillation (AF). We investigated the association of body 
mass index (BMI) on the safety and long-term efficacy of 
pulmonary vein isolation (PVI) for drug-refractory AF.
Methods 414 consecutive patients who underwent 
transcatheter PVI for AF between 2003 and 2013 were 
included. Successful PVI was defined as absence of atrial 
arrhythmia on Holter monitoring or ECG, without and 
with antiarrhythmic drugs during follow-up. Obesity was 
defined as BMI≥30 kg/m².
Results Mean age was 56±10 years, 316 (76%) were 
male, 311 (75%) had paroxysmal AF and 111 (27%) 
were obese. After a mean follow-up of 46±32 months 
(1590 patient-years), freedom from atrial arrhythmia and 
antiarrhythmic drugs was significantly lower in patients 
with obesity compared with non-obese patients (30% 
vs 46%, respectively, P=0.005, log-rank 0.016). With 
antiarrhythmic drugs, freedom from atrial arrhythmia 
was 56% vs 68% (P=0.036). No differences in minor and 
major adverse events were observed between patients 
with obesity and non-obese patients (major 6% vs 3%, 
P=0.105, and minor 5% vs 5%, P=0.512). Sensitivity 
analyses demonstrated that BMI (as continuous variable) 
was associated with PVI outcome (HR 1.08, 95% CI 1.02 to 
1.14, P=0.012).
Conclusion Obesity is associated with reduced efficacy of 
PVI for drug-refractory AF. No relation between obesity and 
adverse events was found.
IntRoduCtIon
Transcatheter pulmonary vein isolation 
(PVI) using radiofrequency energy is a wide-
spread and well-established technique for 
the treatment of atrial fibrillation (AF).1–3 
Current guidelines indicate that PVI should 
be considered even before antiarrhythmic 
drugs (AADs) have failed in patients with 
paroxysmal AF.2 Catheter ablation is superior 
to AADs for rhythm control in symptomatic 
paroxysmal AF4–6 and can also be performed 
successfully for persistent or long-standing 
persistent AF.7 However, radiofrequency 
PVI has only shown moderate success at 
long-term follow-up.8–10 Several comorbidi-
ties increase the risk for AF.11 Obesity is an 
independent risk factor for the develop-
ment and perpetuation of AF11 and nega-
tively influences success rates of PVI at 1-year 
follow-up.12 The recent ARREST-AF trial 
showed that aggressive risk factor manage-
ment improves long-term outcomes of AF 
ablation.12 Also, if weight loss is sustained at 
long-term follow-up, reduction of AF burden 
and maintenance of sinus rhythm are signif-
icantly higher compared with patients with 
weight fluctuation.13 The aim of the present 
study was to investigate long-term outcome 
in consecutive patients undergoing a PVI 
Key questions
What is already known about this subject?
 ► The recent ARREST-AF trial showed that aggressive 
risk factormanagement improves long-term 
outcomes of AF ablation. Also, if weight loss 
issustained at long-term follow-up, reduction of 
AF burden and maintenance ofsinus rhythm are 
significantly higher compared to patients with 
weightfluctuation.
What does this study add?
 ► This studydemonstrates that obesity isassociated 
with lower long term success of PVI. Procedural 
safety was comparable between obese andnon-
obese patients.
How might this impact on clinical practice?
 ► Long-termefficacy of PVI seems reduced compared 
to non-obese patients. Therefore, inobese patients 
weight loss together with management of other risk 
factorsshould be considered to reduce AF burden 
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strategy and to assess procedural safety in patients with 
obesity versus non-obese patients with AF.
MetHods
Patient population
We retrospectively analysed all patients scheduled for 
a first PVI between 2003 and 2013 at the University 
Medical Center Groningen, the Netherlands. All consec-
utive patients had highly symptomatic AF and failed at 
least one AAD. Exclusion criteria for PVI were significant 
underlying heart diseases and age <18 years or >80 years 
and <12 months follow-up. Body mass index (BMI) was 
determined for all patients at the time of ablation. BMI 
was calculated by dividing bodyweight in kilograms by the 
square of the height in metres. Obesity was defined as 
BMI≥30 kg/m2. Patients provided informed consent to 
the ablation procedure. All data were collected following 
our institutional protocol (see Follow-up section) and 
concerned standard patient care. Due to the observa-
tional nature of the study, no further specific investiga-
tion was requested to the patients. Patients’ data privacy 
was granted by coding the database, according to the 
rules of Good Clinical Practice and Dutch Privacy Law.
transcatheter radiofreqency PVI strategy
The transcatheter wide circumferential PVI was 
performed as described previously.14 15 During the 10-year 
study period, the PVI procedure evolved according to 
technical modifications. Briefly, point-by-point ablation 
wide antral lines were created around the pulmonary 
veins. For the first procedures, radiofrequency  energy 
was delivered with a non-irrigated ablation catheter, later 
on this was an irrigated tip. In the initial patients, PVI 
was assessed with pacing within the pulmonary veins to 
conform exit block. From 2011 a circular catheter was 
used to confirm entrance and exit block. During the first 
procedure, no additional ablation lines were made. In 
case the first PVI was unsuccessful, repeat PVI procedures 
were performed when symptomatic atrial arrhythmias 
were present (>3 months after initial PVI), in consulta-
tion with the patient and treating physician. Additional 
(linear) ablation was performed at the discretion of the 
treating electrophysiologist.
Following PVI, oral anticoagulation was immedi-
ately restarted after the procedure, and low-molecu-
lar-weight-heparin was stopped when International 
Normalized Ratio (INR) >2.0 was reached. Oral antico-
agulation treatment was given for at least 3 months and 
thereafter continued based on the CHADS2-score and 
later on the CHADS2VA2Sc.
1 2 AADs were discontinued 
after the first three months blanking period if the patient 
was free from AF recurrence.
Follow-up
Patients visited our clinic at 3, 6 and 12 months post PVI. 
Thereafter, patients were seen annually or on indica-
tion. To assess the occurrence of (a)symptomatic atrial 
arrhythmias, at 6 months 48–96-hour Holter monitoring 
was performed, and at 12 months 24-hour Holter moni-
toring was performed. At each visit a routine 12-lead 
ECG was performed, and when atrial arrhythmia was 
detected, a 12-lead rhythm strip (>30 s) was recorded. In 
case of symptomatic recurrence without documentation, 
event recording was performed to confirm and classify 
the atrial arrhythmia. Follow-up data were censored for 
patients who reached the primary endpoint or had been 
followed through 1 December 2015.
endpoints
Primary endpoint was freedom of atrial arrhythmias, 
that is, no evidence of AF, atrial flutter or other atrial 
arrhythmias with a duration>30 s, without use of AADs at 
the end of follow-up. Procedural safety was investigated 
by reporting the occurrence of periprocedural  and 
procedural minor or major adverse events. Major adverse 
events were defined as those that resulted in death or 
permanent injury. Also registered as major adverse events 
were temporarily injuries that required intervention 
or specific treatment, (eg, stroke, transient ischaemic 
attack, major bleeding requiring surgery or blood trans-
fusion or >2.0 points haemoglobin decrease, cardiac 
tamponade and/or perforation, significant or sympto-
matic pulmonary vein stenosis>70%, pericarditis and/
or pericardial effusion, myocardial infarction, phrenic 
nerve lesion, pneumothorax, pneumonia and other not 
predefined events). Minor adverse events were defined 
as bleeding from the femoral artery/vein, femoral aneu-
rysm not requiring intervention, pericardial effusion not 
requiring intervention and asymptomatic pulmonary 
vein stenosis.16
statistics
Baseline descriptive statistics are presented as mean±SD or 
median (range) for continuous variables, if appropriate, 
and counts with percentages for categorical variables. 
Differences between subgroups, in terms of patient char-
acteristics at baseline, different follow-up times and end 
of study, were evaluated by Student’s t-test or the Mann-
Whitney U test, depending on normality of the data. χ2 or 




 2 July 2018 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2017-000771 on 16 M
ay 2018. Downloaded from
 
3De Maat GE, et al. Open Heart 2018;5:e000771. doi:10.1136/openhrt-2017-000771
Arrhythmias and sudden death
Fisher’s exact test was used for comparison of categorical 
variables. By means of Cox-proportional hazard analyses 
the association of any increase in BMI with the primary 
outcome was assessed. Model 1 is adjusted for age and 
sex, model 2 for age, sex, self-reported obstructive sleep 
apnoea syndrome (OSAS), previous class I or III AAD use, 
LA diameter, AF duration, AF type, chronic heart failure 
and total number of PVI. Model 3 is adjusted for covari-
ates of model 2 and also for the other components of the 
CHADS2VA2Sc, not included in model 2: hypertension, 
diabetes, vascular disease and stroke. No violations of the 
proportional hazards assumptions were found. All tests of 




A total of 414 consecutive patients were included in this 
study. Patient characteristics are shown in table 1. Mean 
age was 56±10 years. Time since first AF diagnosis was 63 
(IQR 29–118) months. AF was paroxysmal in 311 (75%), 
mean BMI was 27.8±4.1 kg/m². Among all patients, 111 
(27%) were obese (BMI≥30 kg/m2) and 25 (6%) had 
a BMI≥35 kg/m2. Distribution of number of patients 
by BMI is shown in figure 1. Comparing patients with 
obesity (BMI≥30 kg/m2) versus non-obese patients 
(BMI<30 kg/m2), several differences were observed: 
chronic systolic heart failure (left ventricular ejection 
fraction (LVEF)≤35%), 10% versus 4%, P=0.034, hyper-
tension 65% versus 46%, P=0.001, self-reported OSAS 7% 
versus 2%, P=0.013. Also left atrial  diameter was larger in 
patients with obesity versus non-obese patients (44±5 mm 
vs 41±7 mm, P<0.001).
PVI outcome in the total population
After a mean follow-up of 46±32 months (1590 patient-
years; median 37, IQR 19–67), a total of 733 proce-
dures were performed, with a median of 2.0 (range 
1–5) ablations per patient. Of all patients, 56% under-
went multiple ablation procedures. Overall long-term 
freedom from atrial arrhythmia and AAD was 42% 
(172/414 patients). With AAD this was 65% (268/414 
patients).
PVI outcome according to obesity
After a mean follow-up of 46±32 months (1590 patient-
years), freedom from atrial arrhythmia and AADs was 
significantly lower in patients with obesity compared with 
non-obese patients (30% vs 46%, respectively, P=0.005, 
log-rank 0.016) (table 2 and figure 2). With AADs, 
freedom from atrial arrhythmia was 56% versus 68% 
(P=0.036) (table 2).
There was no difference between both groups in 
median number of procedures (P=0.500).







Age, mean±SD (years) 56±10 56±10 56±10 0.859
Males, n (%) 316 (76%) 236 (78%) 80 (73%) 0.298
Chronic heart failure, n (%) 24 (6%) 13 (4%) 11 (10%) 0.034
Diabetes mellitus, n (%) 21 (5%) 12 (4%) 9 (8%) 0.124
Previous stroke, n (%) 17 (4%) 11 (4%) 6 (5%) 0.407
Hypertension, n (%) 213 (51%) 141 (46%) 72 (65%) 0.001
Vascular disease, n (%) 47 (11%) 36 (12%) 11 (10%) 0.726
CHADS2VA2Sc score>1, n (%) 142 (34%) 94 (31%) 48 (43%) 0.019
Hypercholesterolaemia, n (%) 79 (19%) 59 (19%) 20 (18%) 0.888
Thyroid dysfunction, n (%) 35 (9%) 21 (7%) 14 (13%) 0.072
Self-reported OSAS, n (%) 13 (4%) 5 (2%) 8 (7%) 0.013
Time since first AF episode, median (IQR) (months) 63 (29–118) 66 (30–121) 48 (23–108) 0.073
Paroxysmal AF, n (%) 311 (75%) 235 (77%) 76 (68%) 0.095
Non-paroxysmal AF, n (%) 103 (25%) 69 (23%) 34 (32%) 0.095
LA diameter parasternal, mm (mean±SD) 42±6 41±7 44±5 <0.001
LVEF, mean±SD 57±6 58±5 57±7 0.234
AAD use 
  Class I or III, n (%) 275 (72%) 200 (66%) 75 (68%) 0.921 
  Amiodarone, n (%) 93 (24%) 58 (19%) 35 (32%) 0.010 
AAD, antiarrhythmic drugs; AF, atrial fibrillation; BMI, body mass index; LVEF, LA left atrial, left  ventricular ejection fraction; 
OSAS, obstructive sleep apnoea syndrome.
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Adverse event according to obesity
Table 2 shows the periprocedural and procedural minor 
or major adverse events. In 37 (9%) patients, adverse 
events occurred, being major in 16 (4%) patients and 
minor in 21 (5%) patients. There was no in-hospital 
mortality. No differences in minor and major adverse 
events were observed between patients with obesity and 
non-obese patients (major 6% vs 3%, P=0.105, and minor 
5% vs 5% P=0.512, figure 3).
Association of BMI and PVI outcome
As sensitivity analyses, we performed multivariate 
Cox-proportional hazard analyses and assessed whether 
an increase in BMI (modelled as continuous covariate) 
was associated with an increased risk atrial arrhythmia 
recurrence. No violations of the proportional hazards 
assumptions were found. Table 3 shows the outcome 
of different models. When adjusting for the covariates 
included in model 2, any increase in BMI was asso-
ciated with failure of PVI with an HR of 1.09 (95% CI 
1.02 to 1.16), P=0.039. Model 3 showed that any increase 
Table 2 Efficacy and safety outcomes of multiple procedure follow-up
Total BMI<30 BMI≥30 P values
Total n, PVI median (range) 2.0 (1–5) 2.0 (1–4) 2.0 (1–5) 0.505
Multiple procedure success
  12 months FU no AAD, n (%) 119 (29%) 93 (31%) 26 (23%) 0.178
  12 months with and without AAD, n (%) 221 (53%) 163 (54%) 58 (52%) 0.911
  Long-term FU no AAD, n (%) 172 (42%) 139 (46%) 33 (30%) 0.005
  Long-term FU with and without AAD, n (%) 268 (65%) 206 (68%) 62 (56%) 0.036
Major adverse events
  Procedure-related death 0 0 0
  Cardiac tamponade/perforation 9 5 4
  Thromboembolic event 4 2 2
  Air-embolic event 2 2 1
  Total (multiple procedures) 16 (4%) 9 (3%) 7 (6%) 0.105
Minor adverse events
  Femoral bleeding/aneurysm/AVF 14 9 5
  Pericardial effusion no intervention 4 3 1
  Phrenic nerve lesion 1 1 0
  Pulmonary vein stenosis (asymptomatic) 1 1 0
  Pericarditis 1 1 0
  Total (multiple procedures) 21 (5%) 15 (5%) 6 (5%) 0.512
Major or minor adverse events (multiple procedures)  37 (9%) 24 (8%) 13 (12%) 0.158
AAD, antiarrhythmic drugs; AVF, arterial venous fistula; BMI, body mass index; FU, follow-up; PVI, pulmonary vein isolation.
Figure 2 Long-term freedom from atrial arrhythmia and 
antiarrhythmic drugs for patients with obesity versus non-
obese patients following multiple procedures. BMI, body 
mass index.
Figure 3 Major and minor adverse events. BMI, body mass 
index; PVI, pulmonary vein isolation.
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of BMI was associated with failure of PVI with an HR of 
1.09 (95% CI 1.01 to 1.16), P=0.017.
dIsCussIon
This retrospective and observational study demonstrates 
that obesity is associated with lower >1-year success of 
PVI. Procedural safety was comparable between patients 
with obesity and non-obese patients.
obesity as cause of AF
Obesity is an important health problem with an 
increasing prevalence. There is abundant evidence for 
the involvement of obesity in the development of AF. 
Individuals with obesity have up to 2.4-fold increased risk 
for new-onset AF.17 Several mechanisms may underlie the 
relation between obesity and new-onset AF. It might be 
related to structural and electrophysiological remodel-
ling caused by elevated end-diastolic pressure, inflamma-
tion and increased plasma volume.18 Epicardial adipose 
tissue might cause a paracrine effect, acting through 
inflammatory markers and adipokines lead to enhanced 
fibrosis. Fatty infiltration of the atrium can shorten action 
potential duration. On top of this, local fat depots can 
cause an arrhythmogenic effect on the atria. In general, 
obesity is a known cause of hypertension and diabetes, 
which are both known to promote atrial fibrosis. Animal 
models of obesity demonstrated increased levels of atrial 
fibrosis and higher susceptibility and sustainability of 
AF. In humans, electro-anatomical mapping in patients 
with obesity showed areas of low voltages indicative of 
increased atrial fibrosis.18 Weight loss has been associated 
with a decrease of the AF burden in patients.19 Also, in 
human studies cardiac fat quantity has been proven to 
be related to AF severity and negatively influence abla-
tion results. Following weight reduction, lower levels of 
inflammatory markers were measured and electro-an-
atomical mapping demonstrated recovery of atrial volt-
ages.13 In our study, hypertension, chronic heart failure 
and an enlarged atrial size, all parameters associated 
with a lower success rate of rhythm control, were more 
frequently present in patients with obesity.3 This is in 
accordance with the literature; the relationship between 
diastolic impairment and obesity has been established by 
other groups.
Influence of obesity on PVI outcome
More and more data become available on obesity and 
atrial arrhythmia recurrences following PVI. A report of 
226 patients with symptomatic, drug-refractory parox-
ysmal and persistent AF (mean BMI 26.6±3.5 kg/m²) 
showed that BMI was not predictive for AF recurrence 
at a mean follow-up of just over 1 year, although a trend 
to a higher AF recurrence was found in patients with 
higher BMI.20 Cha et al showed similar results in their 
study of 523 symptomatic, medication-refractory patients 
with AF (58% paroxysmal, 42% persistent or permanent 
AF) undergoing PVI. The study showed no difference 
in success of catheter ablation between the groups of 
BMI>25 (18%), BMI 25–29.9 kg/m² (44%) and BMI≥30 
(38%) at 12–24 months follow-up.21 However, the main 
finding of our study is that we observed a lower success 
rate of PVI in patients with obesity versus non-obese 
patients during >1-year follow-up. Differences between 
these studies may be explained by differences in clin-
ical characteristics of the patients and follow-up dura-
tion. Of note, we also observed no difference in efficacy 
during the first year of follow-up, but only after long-term 
follow-up. The results of the present study seem to be in 
accordance with the recently published data by Sanders 
et al, who demonstrated that aggressive risk factor reduc-
tion including weight loss improves the outcome of PVI 
in patients with obesity.12 The >1-year freedom from atrial 
arrhythmias in our study is comparable to long-term effi-
cacy rates reported by others.7–9 22 Also, the reported 
adverse events rates are comparable.16
Clinical relevance
Since both obesity and AF pose an epidemic threat, it is 
important to recognise that AF is not only more frequent 
in patients with obesity but also that long-term efficacy of 
PVI seems reduced compared with non-obese patients. In 
order to improve long-term results of PVI, patient selection 
is pivotal.23 Therefore, as stated in the new AF guidelines, 
in patients with obesity, weight loss, together with manage-
ment of other risk factors, should be considered to reduce 
AF burden and symptoms before invasive treatment modal-
ities are deployed.3 Risk factor modification and weight loss 
might even result in higher treatment success by reducing 
substrate and slowing down AF progression.
strengths and limitations
Our study was retrospective, precluding definite conclu-
sions about cause–effect relations of obesity and PVI 
outcome. However, strength of our study was that we 
had a >1500 patient-years follow-up in most patients with 
extensive Holter recordings, which increased the prob-
ability of observing any atrial arrhythmia recurrence. 
First, short and asymptomatic episodes of AF might be 
undetected. Second, obesity is often accompanied by 
more comorbidities, so obesity may reflect a clustering of 
Table 3 Sensitivity analyses of the association of body 
mass index and long-term outcome after multivariable 
adjusted analyses
HR (95% CI) P values
Model 1 1.08 (1.02 to 1.14) 0.012
Model 2 1.09 (1.02 to 1.16) 0.039
Model 3 1.09 (1.01 to 1.16) 0.017
Model 1 is adjusted for age and sex. Model 2 is adjusted for 
age, sex, obstructive sleep apnoea syndrome, previous class I 
or III antiarrhythmic drug use, left atrial diameter, atrial fibrillation 
duration, atrial fibrillation type, chronic heart failure and total 
number of pulmonary vein isolation procedures. Model 3 adjusted 
for all factors mentioned previously and also hypertension, 
diabetes, vascular disease and stroke.
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cardiovascular risk factors that may impact PVI outcome, 
though even after multivariable adjustment the associa-
tion of BMI with PVI outcome remained. Third, the inci-
dence of OSAS was low and may been caused by the fact 
we only collected self-reported OSAS, and no structural 
polysomnography was performed in our cohort. Fourth, 
the present analysis did not offer the opportunity to look 
into temporal associations between weight gain of loss and 
success of PVI. Finally, as described above, the transcath-
eter ablation strategy evolved over time with the introduc-
tion of improved equipment and was applied equally in 
all patients, regardless of the body mass composition.
ConClusIon
Obesity is associated with reduced efficacy of PVI for 
drug-refractory AF. No relation between obesity and 
procedural adverse events was found. This emphasise that 
risk factor reduction before ablation including weight 
loss should be implemented in the work-up of patients 
with symptomatic AF referred for AF ablation.
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